BioSpace

COPENHAGEN, Denmark, July 10, 2026 (GLOBE NEWSWIRE) -- Nine new Challenge Programme grants from the Novo Nordisk Foundation will support ambitious research across fungal diseases, cardiometabolic disease, soil health and non-equilibrium biological systems. With a European expansion, the 2026 awards unite strong research groups and diverse expertise across Europe in the pursuit of novel knowledge addressing major scientific challenges.

SILICON VALLEY, Calif., July 9, 2026 /PRNewswire/ -- TibaRay, a Silicon Valley medical technology company founded on Stanford University research, announced today that its first Galactica™ cancer treatment systems have entered manufacturing. The milestone marks a major step for TibaRay as it moves its next-generation radiotherapy technology closer to patients. The milestone marks a major step for TibaRay as it moves its next-generation radiotherapy technology closer to patients.

Continued Growth Underpins First Full Year Net Revenue of US$115M NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026.

Global CRO highlights multi-regional trial delivery, early-phase Australia advantages, and expanding support for biotech sponsors across Asia and China ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia–Taiwan 2026, taking place 15–19 July at the Taipei Nangang Exhibition Center (TaiNEX), Taipei.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on October 15, 2026, to shareholders of record as of September 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026.